share_log

VBI Vaccines Announces Presentation Of Physician-Initiated Compassionate Use Data Of 3-Antigen Hepatitis B Vaccine At 2022 International HBV Meeting; Presentation Was Monday, Sept. 19

VBI Vaccines Announces Presentation Of Physician-Initiated Compassionate Use Data Of 3-Antigen Hepatitis B Vaccine At 2022 International HBV Meeting; Presentation Was Monday, Sept. 19

VBI疫苗公司宣布在2022年国际乙肝会议上展示医生发起的3-抗原乙肝疫苗的同情使用数据；展示时间为9月1日星期一。19个
Benzinga Real-time News ·  2022/09/21 08:06

VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that data from the physician-initiated compassionate use of VBI's 3-antigen hepatitis B vaccine in four adults chronically infected with hepatitis B virus (HBV) were presented in a poster session at the 2022 International HBV Meeting in Paris, France, on September 19.

VBI疫苗公司(纳斯达克代码：VBIV)(VBI)是一家以免疫学为动力的生物制药公司，致力于强有力的疾病预防和治疗。该公司今天宣布，9月19日在法国巴黎举行的2022年国际乙肝会议上，医生发起的同情使用VBI3抗原乙肝疫苗的数据在2022年法国巴黎国际乙肝会议上公布。

Poster Presentation Details

海报展示详情

  • Title: Therapeutic vaccination of chronically HBV infected patients with low-level of HBsAg using a combination of a third generation PreS/S vaccine (Sci-B-Vac) and a nucleoside analogue
  • Session: Poster Session I
  • Date: Monday, September 19, 2022
  • Presenter: Hedwig Roggendorf, M.D., Institute of Molecular Immunology and Experimental Oncology, University Hospital Rechts der Isar, Technical University of Munich
    • Event Website:
  • 标题：使用第三代PreS/S疫苗(SCI-B-VAc)和核苷类似物联合接种低水平HBs慢性感染患者的治疗性疫苗
  • 会话：招贴会I
  • 日期：2022年9月19日(星期一)
  • 主讲人：德国慕尼黑工业大学分子免疫学和实验肿瘤学研究所
    • 活动网站：
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发